Back to top
more

Sucampo Pharmaceuticals, Inc. (SCMP)

(Real Time Quote from BATS)

$18.00 USD

18.00
NA

+0.05 (0.28%)

Updated Feb 13, 2018 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Arpita Dutt headshot

3 Overlooked Drug Stocks to Watch Out for in 2017

As we start the New Year, here is a look at 3 drug stocks that have not been in the news much but have been witnessing upward estimate revisions and sport a strong Zacks Rank.

    Zoetis (ZTS) Thrives on Product Portfolio, Risks Persist

    On Dec 29, 2016, we issued an updated research report on Zoetis Inc. (ZTS).

      Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife

      Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife

        5 Profitable Stocks to Buy for Great Returns

        Net income ratio gives us the exact profit level of a company and reflects the percentage of net income to total sales revenue.

          Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up

          Shares of Portola (PTLA) surged 33.8% after the FDA granted priority review to anticoagulant, betrixaban. Betrixaban was also accepted by the EMA for review.

            Tirthankar Chakraborty headshot

            4 Top Stocks with Earnings Acceleration to Buy in 2017

            These stocks have witnessed increase in quarter-over-quarter earnings growth within a stipulated frame of time.

              Ironwood, Allergan Report Positive Linzess IBS-C Study Data

              Ironwood (IRWD) and Allergan (AGN) report phase IIb study data on colonic release formulations of Linzess for the treatment of irritable bowel syndrome with constipation.

                Sarepta's (SRPT) Application for DMD Drug Accepted in the EU

                Sarepta Therapeutics, Inc. (SRPT) announced that the European Medicines Agency (EMA) has validated its Marketing Authorization application (MAA) for Exondys 51.

                  Agios Stops Development of PKR Activator AG-519, Stock Falls

                  Shares of Agios (AGIO) tanked 19.4% after the company decided to discontinue the development of its PKR activator, AG-519.

                    Roche (RHHBY) to Terminate Pacifica Bioscience Agreement

                    Roche Holding AG (RHHBY) announced that it intends to terminate its agreement with Pacifica Bioscience.

                      Trovagene to Focus More on Liquid Biopsy Testing Market

                      Trovagene, Inc. (TROV), recently announced that it will increase its focus on the global distribution of kits and systems to clinical research laboratories for the liquid biopsy oncology testing market.

                        athenahealth (ATHN) Reaffirms 2016 View, Guides for 2017

                        athenahealth Inc. (ATHN) reaffirmed its full-year 2016 guidance and issued a stable guidance for 2017.

                          Intuitive Surgical (ISRG) Raises Share Buyback to $3 Billion

                          Intuitive Surgical Inc. (ISRG) increased the authorized amount available under the company's share repurchase program to $3.0 billion.

                            Envision Healthcare Acquires Desert Mountain Consultants

                            Envision Healthcare Corporation (EVHC), a provider of physician-led outsourced medical services to consumers, hospitals and healthcare systems in the U.S., recently announced the acquisition of Desert Mountain Consultants in Anesthesia, Inc.

                              Eli Lilly (LLY) to Offer Discount on Insulin from January

                              Eli Lilly (LLY) announced that the company will offer access to its insulin products at discounted prices, starting Jan 2017.

                                Kite Pharma Enters into Partnership with Vitruvian Networks

                                Kite Pharma (KITE) entered into a strategic partnership with Vitruvian Networks to create a software solution to support commercial availability of T-cell therapies.

                                  Proteon Slips to 52-Week Low on Kidney Disease Study Data

                                  Proteon's (PRTO) shares hit a 52-week low after reporting poor top-line phase III data on vonapanitase in patients with chronic kidney disease.

                                    Repros to Meet with the FDA for Phase III Proellex Program

                                    Repros (RPRX) announced that it has requested a meeting with the FDA to discuss requirements for phase III development of Proellex.

                                      Roche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval

                                      Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia.

                                        Corcept Korlym Positive in Phase I/II Breast Cancer Study

                                        Corcept Therapeutics (CORT) announced encouraging efficacy data from a phase I/II study on Korlym in patients with metastatic triple-negative breast cancer.

                                          Novartis Offers Positive Data on Breast Cancer Drug LEE011

                                          Novartis (NVS) announced results from the phase III MONALEESA-2 study on LEE011 for the treatment of first-line HR+/HER2- advanced breast cancer.

                                            Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails

                                            Horizon Pharma (HZNP) has decided to discontinue the development of Actimmune for Friedreich's ataxia after a phase III study failed to meet key endpoints.

                                              Endo (ENDP) Inks Deal to Return Belbuca Rights to BioDelivery

                                              Endo (ENDP) announced that it has entered into an agreement to return the rights for Belbuca to BioDelivery (BDSI).

                                                Pfizer (PFE) Fined for Price Hike of Anti-Epilepsy Drug in UK

                                                Pfizer (PFE) fined for hiking price of an anti-epilepsy drug by up to 2,600% by the Competition and Markets Authority of the UK.

                                                  Zacks.com featured highlights: Lancaster Colony, Sucampo Pharmaceuticals, Citrix Systems, VMware and Sanchez Energy

                                                  Zacks.com featured highlights: Lancaster Colony, Sucampo Pharmaceuticals, Citrix Systems, VMware and Sanchez Energy